Aliases & Classifications for Mood Disorder

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 15 17
Mood Disorders 54 42 43 15 71
Episodic Mood Disorder 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 43 D019964
NCIt 49 C92200
SNOMED-CT 67 46206005 74421008
UMLS 71 C0525045 C1456434

Summaries for Mood Disorder

MedlinePlus : 42 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to depression and dysthymic disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Peptide ligand-binding receptors. The drugs Pioglitazone and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves a disturbance in mood as the predominant underlying feature.

Wikipedia : 74 Mood disorder, also known as mood affective disorders, is a group of conditions where a disturbance in... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 492)
# Related Disease Score Top Affiliating Genes
1 depression 33.4 SLC6A4 MAOA HTR2A HTR1A DISC2 CRH
2 dysthymic disorder 33.3 SLC6A4 MAOA HTR2A HTR1A DISC2 CRH
3 major depressive disorder 33.3 TPH1 SLC6A4 POMC NR3C1 NPY MAOB
4 schizoaffective disorder 33.3 SLC6A4 HTR2A HTR1A DRD4 DRD2 DISC2
5 postpartum depression 33.2 SLC6A4 MAOA HTR1A CRH COMT BDNF
6 delusional disorder 33.2 TH HTR2A HTR1A DRD4 DRD2 DISC1
7 kleptomania 33.1 SLC6A4 MAOA HTR1A DRD2
8 impulse control disorder 33.0 SLC6A4 MAOB MAOA HTR2A HTR1A DRD4
9 atypical depressive disorder 33.0 SLC6A4 POMC NR3C1 MAOB MAOA HTR2A
10 asperger syndrome 32.9 SLC6A4 MAOB DISC1 COMT BDNF
11 schizophrenia 9 32.9 TH DISC1
12 endogenous depression 32.9 TPH1 TH SLC6A4 POMC NR3C1 NPY
13 bipolar disorder 32.8 TPH1 TH SLC6A4 SLC18A2 NR3C1 MAOA
14 acth-secreting pituitary adenoma 32.8 POMC NR3C1 DRD2 CRH
15 schizophrenia 32.5 TPH1 TH SLC6A4 SLC18A2 POMC NR3C1
16 mental depression 32.0 TPH1 SLC6A4 POMC NR3C1 MAOA HTR2A
17 bipolar i disorder 31.9 SLC6A4 HTR2A HTR1A DRD4 DRD2 COMT
18 avoidant personality disorder 31.8 TPH1 SLC6A4 MAOA HTR1B DRD4 DRD2
19 social phobia 31.7 SLC6A4 MAOA HTR1A DRD2 COMT
20 anxiety 31.7 TPH1 TH SLC6A4 POMC NR3C1 NPY
21 substance abuse 31.7 SLC6A4 NPY MAOA HTR2A HTR1B HTR1A
22 traumatic brain injury 31.6 DRD2 COMT BDNF
23 personality disorder 31.6 TPH1 TH SLC6A4 NR3C1 MAOB MAOA
24 brain injury 31.6 DRD2 COMT BDNF
25 cyclothymic disorder 31.6 HTR2A DRD4 DRD2 DISC1
26 eating disorder 31.6 SLC6A4 POMC NPY HTR2A DRD2 CRH
27 alcohol use disorder 31.6 SLC6A4 HTR2A HTR1B HTR1A DRD2 CRH
28 melancholia 31.6 SLC6A4 POMC MAOA HTR2A HTR1A CRH
29 tardive dyskinesia 31.6 HTR2A DRD2 COMT
30 premenstrual tension 31.5 POMC HTR1A
31 generalized anxiety disorder 31.5 TPH1 SLC6A4 NR3C1 NPY MAOA HTR2A
32 adjustment disorder 31.5 SLC6A4 NPY HTR2A BDNF
33 acute stress disorder 31.5 SLC6A4 POMC NR3C1 CRH BDNF
34 sleep disorder 31.4 TH SLC6A4 POMC HTR2A HTR1A DRD2
35 psychotic disorder 31.4 TPH1 TH SLC6A4 SLC18A2 MAOB MAOA
36 panic disorder 31.4 TPH1 SLC6A4 POMC NPY MAOA HTR2A
37 agoraphobia 31.4 SLC6A4 MAOA HTR2A HTR1A COMT
38 borderline personality disorder 31.4 TPH1 TH SLC6A4 NR3C1 MAOA HTR2A
39 alexithymia 31.3 SLC6A4 HTR1A DRD2 COMT
40 neurotic disorder 31.3 TH SLC6A4 MAOA HTR2A HTR1A BDNF
41 anorexia nervosa 31.3 SLC6A4 POMC NPY MAOA HTR2A HTR1A
42 attention deficit-hyperactivity disorder 31.2 TPH1 TH SLC6A4 SLC18A2 NR3C1 NPY
43 sleep apnea 31.2 SLC6A4 HTR2A BDNF
44 constipation 31.2 TH SLC6A4 NPY BDNF
45 post-traumatic stress disorder 31.2 SLC6A4 POMC NR3C1 NPY MAOB MAOA
46 obsessive-compulsive disorder 31.2 TPH1 SLC6A4 POMC NPY MAOB MAOA
47 cannabis abuse 31.2 HTR1A DRD4 DRD2 COMT BDNF
48 tobacco addiction 31.2 TPH1 SLC6A4 MAOA HTR2A DRD4 DRD2
49 dementia 31.1 TH MAOB MAOA HTR2A HTR1A DRD2
50 sexual disorder 31.1 SLC6A4 POMC HTR2A HTR1A DRD2

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


alexithymia, psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 BDNF COMT CREB1 CRH DISC1 DRD2
2 homeostasis/metabolism MP:0005376 10.3 BDNF COMT CREB1 CRH DISC1 DRD2
3 cardiovascular system MP:0005385 10.26 COMT CREB1 DRD2 HTR1A HTR1B MAOA
4 cellular MP:0005384 10.23 BDNF CREB1 CRH DRD2 HTR1B MAOB
5 growth/size/body region MP:0005378 10.22 BDNF CREB1 CRH DISC1 DRD2 HTR1B
6 endocrine/exocrine gland MP:0005379 10.17 BDNF COMT CREB1 CRH DRD2 HTR1B
7 nervous system MP:0003631 10.16 BDNF COMT CREB1 CRH DISC1 DRD2
8 adipose tissue MP:0005375 10.05 CRH DRD2 HTR1B NPY NR3C1 POMC
9 muscle MP:0005369 9.92 CREB1 DRD2 HTR1B HTR2A NR3C1 SLC18A2
10 no phenotypic analysis MP:0003012 9.76 BDNF CRH DRD2 HTR1A HTR1B NR3C1
11 renal/urinary system MP:0005367 9.5 COMT CRH DRD2 MAOB NPY NR3C1
12 respiratory system MP:0005388 9.23 BDNF COMT CREB1 CRH DRD2 NR3C1

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
5
Histamine Approved, Investigational Phase 4 51-45-6 774
6
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
7
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
8
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
9
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
10
Disulfiram Approved Phase 4 97-77-8 3117
11
Desipramine Approved, Investigational Phase 4 50-47-5 2995
12
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Ziprasidone Approved Phase 4 146939-27-7 60854
15
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
16
Hydroxychloroquine Approved Phase 4 118-42-3 3652
17
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
18
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
19
Azathioprine Approved Phase 4 446-86-6 2265
20
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
21
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
22
Ribavirin Approved Phase 4 36791-04-5 37542
23
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
24
Methohexital Approved Phase 4 151-83-7 9034
25
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
26
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
27
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
28
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
29
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
30
Memantine Approved, Investigational Phase 4 19982-08-2 4054
31
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
32
Infliximab Approved Phase 4 170277-31-3
33
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
34
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
35
Acetaminophen Approved Phase 4 103-90-2 1983
36
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
37
Suvorexant Approved, Investigational Phase 4 1030377-33-3
38
Promethazine Approved, Investigational Phase 4 60-87-7 4927
39
Clonidine Approved Phase 4 4205-90-7 2803
40
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
41
leucovorin Approved Phase 4 58-05-9 6006 143
42
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
43
Lorazepam Approved Phase 4 846-49-1 3958
44
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
45
Metformin Approved Phase 4 657-24-9 14219 4091
46
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
47
Sertraline Approved Phase 4 79617-96-2 68617
48
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
49
Clozapine Approved Phase 4 5786-21-0 2818
50
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 926)
# Name Status NCT ID Phase Drugs
1 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
2 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
3 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
4 Lithium in Cardiac Surgery Related Acute Kidney Injury: A Pilot Study Unknown status NCT03056248 Phase 4 Placebo oral capsule;Lithium Carbonate
5 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
6 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
7 Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders Completed NCT01559857 Phase 4 Pioglitazone;Sugar Pill
8 Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms Completed NCT00912535 Phase 4 Quetiapine extended release tablet;Placebo
9 Endogenous Opioid Activity and Affective State in Insulin Resistant Women Completed NCT02069379 Phase 4 Metformin;Placebo
10 Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana Completed NCT02593734 Phase 4 olanzapine;risperidone;amitryptaline;fluoxetine
11 Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study Completed NCT00177567 Phase 4 lithium carbonate;Depakote-ER;risperidone;olanzapine;paroxetine;bupropion;lamotrigine;venlafaxine;tranylcypromine;mirtazapine
12 An Exploratory Study Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar I and II Patients From Valproic Acid to Depakote ER Completed NCT00211250 Phase 4 Valproic Acid and Depakote ER
13 Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Mood Disorders Through Resources Available in Brazilian Public Health Completed NCT02870283 Phase 4 Lithium;Valproic Acid;Carbamazepine
14 Dynamic Measures of Neurochemistry in Mood Disorders Completed NCT00178828 Phase 4 sertraline;bupropion
15 The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression Completed NCT00030147 Phase 4 Raloxifene;Rimostil;Transdermal Estradiol;Placebo skin patch and placebo tablets
16 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
17 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
18 Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode Completed NCT02918097 Phase 4 Lithium Carbonate;Sertraline;Nortriptyline;Risperidone
19 Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Major Depression Through Resources Available in Brazilian Public Health Completed NCT02901249 Phase 4 sertraline;Nortriptyline;Lithium Carbonate
20 Depakote ER in Bipolar Depression Completed NCT00186186 Phase 4 Depakote ER
21 Prolonging Remission in Depressed Elderly (PRIDE) Completed NCT01028508 Phase 4 lithium and Venlafaxine
22 Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
23 Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI Completed NCT01811147 Phase 4 Selective Serotonin Reuptake Inhibitor (SSRI)
24 Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder Completed NCT00502320 Phase 4 Ramelteon;Placebo
25 Minocycline for Bipolar Disorder Completed NCT01514422 Phase 4 Minocycline
26 Do Antidepressants Reverse the Effects of Early Life Stress on the Brain and Thrombovascular System and Improve Psychological, Neuroendocrine, and Platelet Function: A Study of Men and Women With Childhood Abuse. Completed NCT00166114 Phase 4 Escitalopram;Desipramine
27 Neural Correlates of Emotional Processing in Depressed and Remitted Bipolar and Unipolar Depressed Subjects: An fMRI Investigation Completed NCT00188942 Phase 4 Fluoxetine+Olanzapine;Olanzapine
28 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
29 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres Completed NCT00526877 Phase 4 Risperidone
30 An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
31 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
32 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
33 Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors Completed NCT03449758 Phase 4 SARILUMAB;Azathioprine;Chloroquine;Hydroxychloroquine;Leflunomide;Methotrexate;Sulfasalazine
34 Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial Completed NCT01431092 Phase 4 Placebo;Melatonin
35 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
36 Memantine Augmentation of Lamotrigine Incomplete Response in Bipolar Depression: A Randomized Placebo Controlled Clinical Trial Completed NCT00305578 Phase 4 Memantine;Placebo
37 White Matter and Emotional and Cognitive Control in Late-Onset Depression Completed NCT01728194 Phase 4 Escitalopram
38 Effects of Electroconvulsive Therapy on Serotonin-1A Receptor Binding in Major Depression Completed NCT00922064 Phase 4
39 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
40 A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
41 Short-Term Versus Long-Term Treatment for Severe PMS Completed NCT00318773 Phase 4 sertraline
42 Prozac Treatment of Major Depression: Discontinuation Study Completed NCT00427128 Phase 4 fluoxetine;placebo
43 The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff Completed NCT01462058 Phase 4 Placebo
44 Acute Psychotherapy for Bipolar II Depression Completed NCT01133821 Phase 4 IPSRT plus placebo (IPSRT-PLA);IPSRT plus quetiapine
45 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
46 A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders Completed NCT00253110 Phase 4 risperidone;haloperidol
47 Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia Completed NCT01881763 Phase 4 Ketamine;Methohexital
48 Maintenance Study for Adolescent Depression Completed NCT00508859 Phase 4 Sertraline;placebo
49 Effects of Estradiol on Neural Reward System and Depression in the Perimenopause Completed NCT02255175 Phase 4 Estradiol;Progesterone
50 Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans Completed NCT00288782 Phase 4 Mirtazapine

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Divalproex Sodium
lamotrigine
Mood Stabilizer [EPC]
Sodium Valproate
Valproic Acid

Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

40
Brain, Cortex, Testes, Heart, Pituitary, Thyroid, Amygdala

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 16484)
# Title Authors PMID Year
1
Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. 54 61
20060128 2010
2
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 54 61
19936882 2010
3
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. 54 61
20072116 2010
4
Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. 54 61
19931869 2010
5
Altered gene expression of histone deacetylases in mood disorder patients. 54 61
19767015 2010
6
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. 54 61
20043006 2010
7
Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. 54 61
20010318 2010
8
A possible role of neuropeptide Y in depression and stress. 54 61
19782662 2010
9
Culture-gene coevolution of individualism-collectivism and the serotonin transporter gene. 54 61
19864286 2010
10
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. 54 61
20016223 2010
11
Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect. 54 61
19517574 2010
12
Endocannabinoids and their role in fatty liver disease. 54 61
20460921 2010
13
kappa-Opioid receptor signaling and brain reward function. 54 61
19804796 2009
14
Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats. 54 61
19576731 2009
15
Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. 54 61
19584773 2009
16
G72/G30 (DAOA) and juvenile-onset mood disorders. 54 61
19089835 2009
17
Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. 54 61
19906241 2009
18
A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. 54 61
19589503 2009
19
Relationships between angry-impulsive personality traits and genetic polymorphisms of the dopamine transporter. 54 61
19368898 2009
20
The role of beta-endorphin in the pathophysiology of major depression. 54 61
19647870 2009
21
Mutation screen and association analysis of the glucocorticoid receptor gene (NR3C1) in childhood-onset mood disorders (COMD). 54 61
19089807 2009
22
Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. 54 61
19375869 2009
23
Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. 54 61
19376528 2009
24
Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. 54 61
19224106 2009
25
Management of non-motor complications in Parkinson's disease. 54 61
19711120 2009
26
Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. 54 61
19375070 2009
27
Increased risk of suicide attempt in mood disorders and TPH1 genotype. 54 61
18977032 2009
28
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. 54 61
19428704 2009
29
Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis. 54 61
19530966 2009
30
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. 54 61
19233297 2009
31
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. 54 61
19361869 2009
32
Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. 54 61
18817811 2009
33
Partial regulation of serotonin transporter function by gamma-synuclein. 54 61
19429025 2009
34
Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress. 54 61
18317463 2009
35
Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. 54 61
18704093 2009
36
Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. 54 61
18849121 2009
37
Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. 54 61
18715570 2009
38
[BDNF measurement in stress-related mood disorders: a review of clinical studies]. 54 61
20013430 2009
39
Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population. 54 61
19224413 2009
40
Circadian polymorphisms associated with affective disorders. 54 61
19166596 2009
41
Disruption of the circadian timing systems: molecular mechanisms in mood disorders. 54 61
19708722 2009
42
Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. 54 61
18976638 2009
43
Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. 54 61
18574609 2008
44
Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. 54 61
19018231 2008
45
The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. 54 61
19032713 2008
46
BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. 54 61
19018714 2008
47
Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative post-mortem study. 54 61
18760907 2008
48
Increased expression of splicing factor SRp20 mRNA in bipolar disorder patients. 54 61
18281098 2008
49
Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics. 54 61
18781861 2008
50
Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. 54 61
18664999 2008